Clinical Trials on Post-essential Thrombocythemia Myelofibrosis in Japan
Total 18 results
-
PfizerTerminatedPrimary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisUnited States, Japan
-
Novartis PharmaceuticalsCompletedPrimary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-MyelofibrosisBelgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
-
Incyte CorporationRecruitingAnemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia MyelofibrosisUnited States, France, Italy, Japan, United Kingdom, Canada
-
Incyte CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera MyelofibrosisUnited States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia MyelofibrosisUnited States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
-
Incyte CorporationActive, not recruitingPrimary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera MyelofibrosisUnited States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
-
Novartis PharmaceuticalsCompletedAsian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFPrimary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MFTaiwan, Japan, Korea, Republic of, China
-
Incyte CorporationRecruitingMyelofibrosis | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome | Relapsed or Refractory Primary Myelofibrosis | Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) | ET...United States, Spain, Japan, Italy, Finland, United Kingdom, Canada
-
Novartis PharmaceuticalsCompleted
-
CelgeneActive, not recruiting
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
ShireCompletedEssential Thrombocythemia (ET)Japan
-
PharmaEssentiaMedpace, Inc.; EPS International; Brightech InternationalActive, not recruitingEssential ThrombocythemiaUnited States, Canada, Korea, Republic of, China, Hong Kong, Singapore, Taiwan, Japan
-
Merck Sharp & Dohme LLCRecruitingEssential ThrombocythemiaPoland, Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy, Netherlands
-
CelgeneRecruitingPrimary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera MyelofibrosisFrance, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
-
Novartis PharmaceuticalsRecruitingAcute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Thalassemia | Graft Versus Host DiseaseKorea, Republic of, Italy, Belgium, Japan, Germany, Australia, Bulgaria, Chile, China, Denmark, Greece, Hungary, Israel, Lebanon, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Thailand, India, Mexico, Turkey, Fran...